SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
195 hedge funds and large institutions have $458M invested in SANGAMO THERAPEUTICS INC in 2022 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 57 increasing their positions, 56 reducing their positions, and 28 closing their positions.
87% more call options, than puts
Call options by funds: $3.64M | Put options by funds: $1.95M
1.37% more ownership
Funds ownership: 52.79% → 54.16% (+1.4%)
1% more funds holding
Funds holding: 193 → 195 (+2)
7% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 28
2% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 56
20% less capital invested
Capital invested by funds: $571M → $458M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$9.34M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.12M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.73M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.65M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
-$4.04M |
| 2 |
Millennium Management
New York
|
-$3.65M |
| 3 |
Morgan Stanley
New York
|
-$2.56M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.39M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$2.28M |
SGMO Hedge Fund Activity: Q1 2022 in Review
195 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2022, worth a combined $458M — down 20% from $571M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SGMO positions and 28 closed out — a net gain of 2 holders — while 57 added to existing stakes and 56 trimmed.
The largest buyer was State Street, adding an estimated $9.34M. The largest seller was Lombard Odier Asset Management (Switzerland), cutting an estimated $4.04M.
- 195 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2022, up from 193 in Q4 2021.
- Funds reported $458M of SANGAMO THERAPEUTICS INC stock for Q1 2022, down 20% quarter-over-quarter.
- 30 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2022 and 28 closed out, a net change of +2 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q1 2022 was State Street, an estimated $9.34M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q1 2022 was Lombard Odier Asset Management (Switzerland), an estimated $4.04M sold.
Based on aggregated 13F filings for Q1 2022.